Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 17, 2017

Study Completion Date

May 25, 2021

Conditions
Glycogen Storage Disease Type III
Interventions
DIETARY_SUPPLEMENT

FAXE Kondi

Sucrose and glucose containing softdrink

DIETARY_SUPPLEMENT

Faxe Kondi Free

Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.

Trial Locations (1)

2100

Copenhagen Neuromuscular Center, department 3342, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT02448667 - Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies | Biotech Hunter | Biotech Hunter